The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum
Year: 2024
Type: article
Abstract: This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single-time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.
Source: Diabetes
DOI: 10.2337/dbi24-0028
Institutions: Vanderbilt University Medical Center, Cedars-Sinai Medical Center, University of Arizona, University of Basel, University Hospital of Basel, Amsterdam University Medical Centers, Lund University, Consejo Superior de Investigaciones Científicas, Instituto de Agroquímica y Tecnología de Alimentos, University of Gothenburg, Rutgers, The State University of New Jersey
Language: English
Topic: Gut microbiota and health
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Funders: National Science Foundation, Ministerio de Ciencia, Innovación y Universidades, European Commission, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, ZonMw, Novo Nordisk, Göteborgs Universitet, Novo Nordisk Fonden, National Institutes of Health, Agencia Estatal de Investigación, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences
Awards: G1338988596, G1622815974, G1671396359, G2202250497, Is Obesity an Infectious Disease?: Gut bacterial and fungal translocation as an underappreciated driver of visceral adipose expansion., G2262748287, G2975900969, G300979063, G3473515017, G3480869486, G4042783231, G4115475925, G4857567810, G5080475149, Stratification of Obesity Phenotypes to Optimize Future Therapy, G6731524417, G6911258424, G7805626310, G824153803, G8497050386, G8690818240, Investigating the impact of GPR35-mediated cytokine release by macrophages/dendritic cells on epithelial integrity in eosinophilic esophagitis, Rutgers Center for Environmental Exposure and Disease (CEED), G979940031
OpenAlex ID: W4399974039